Didrik F. Vestrheim - Concepedia

Author

Didrik F. Vestrheim

Norwegian Institute of Public Health ORCID

Also Known As

D F Vestrheim, D. F. VESTRHEIM, D. F. Vestrheim, D.F. Vestrheim, Didrik F Vestrheim, Didrik F. Vestrheim, Didrik Frimann Vestrheim, Didrik Vestrheim, Vestrheim, Didrik

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Norwegian Institute of Public Health European Centre for Disease Prevention and Control Public Health England Statens Serum Institut National Institute for Public Health and the Environment

About

Didrik F. Vestrheim is an author at Norwegian Institute of Public Health specializing in medicine, infection control, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.2K
2	Epidemiology	10	11	855
3	Public Health	3	3	233
4	Health Sciences	2	2	195
5	Global Health	1	1	57

Didrik F. Vestrheim

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway Anneke Steens, Marianne A. Riise Bergsaker, Ingeborg S. Aaberge, Vaccine VaccinationVaccine SafetyInvasive Pneumococcal DiseasePrompt Effect13-Valent Vaccine	2013	195
Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010 Magnus Unemo, Daniel Golparian, Gaute Syversen, Eurosurveillance Klebsiella PneumoniaeVerified Clinical FailuresFirst-line Cefixime TreatmentDrug ResistanceGonorrhoea Treatment	2010	185
Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination Germaine Hanquet, Pavla Křížová, Palle Valentiner‐Branth, Thorax	2018	165
Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway Didrik F. Vestrheim, Ø Løvoll, Ingeborg S. Aaberge, Vaccine VaccinationVaccine SafetyInvasive Pneumococcal DiseasePreventive MedicinePediatrics	2008	163
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe Germaine Hanquet, Pavla Křížová, Shamez Ladhani, Emerging infectious diseases Ipd IncidenceImmunodeficienciesImmunologyBroader Serotype ProtectionVaccine Surveillance	2021	155
Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study Camelia Savulescu, Pavla Křížová, A. Lepoutre, The Lancet Respiratory Medicine VaccinationVaccine SafetyInvasive Pneumococcal DiseaseObservational Multicentre StudyPediatrics	2017	117
Impact of a Pneumococcal Conjugate Vaccination Program on Carriage among Children in Norway Didrik F. Vestrheim, E. Arne Høiby, Ingeborg S. Aaberge, Clinical and Vaccine Immunology	2010	114
Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study Camelia Savulescu, Pavla Křížová, Palle Valentiner‐Branth, Vaccine VaccinationVaccine SafetyInvasive Pneumococcal DiseaseVaccine DevelopmentPediatrics	2022	108
Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015 Alex‐Mikael Barkoff, Jussi Mertsola, Denis Piérard, Eurosurveillance	2019	96
Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012 Anne Zeddeman, Marjolein van Gent, C.J. Heuvelman, Eurosurveillance	2014	88

Page 1